Product Information

AMITIZA 8 MCG CAPSULE is a brand product labeled by SpecGx LLC, priced at $6.4677 per EA under NDC 23635050860. Its NADAC has been published 101 times since Sep 18, 2024.

FDA first approved this application on Jan 31, 2006. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.

The High Outlier badge above means this manufacturer's average price in the lubiprostone market falls above Q3 + 1.5·IQR across all competing manufacturers. We only apply this flag in markets with four or more competitors. Full definition: glossary → outlier.

Price Statistics

The NADAC for AMITIZA 8 MCG CAPSULE has been published 101 times since Sep 18, 2024, and over the history we have for it it has held within roughly two percent of its current level. The table below summarizes its recorded NADAC range and movement.

Generic Alternatives

The matcher finds 1 manufacturer offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 92% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.